Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker DBVT · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Oct 28, 2026 | Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children NCT03859700 · Peanut Allergy DBV712 250 mcg | DBVT DBV Technologies | Phase 3 | Completed | 304 | May 13, 2025 | Registry ↗ |
| Oct 8, 2026 | Safety Study of Viaskin Peanut to Treat Peanut Allergy NCT02916446 · Peanut Allergy Viaskin Peanut 250 µg, Placebo | DBVT DBV Technologies | Phase 3 | Completed | 393 | Sep 22, 2017 | Registry ↗ |
| Jul 22, 2026 | Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT… NCT07003919 · Allergy, Peanut Allergy DBV712 250 mcg, Placebo | DBVT DBV Technologies | Phase 3 | Active, not recruiting | 480 | Nov 2026 | Registry ↗ |
| Jan 22, 2026 | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age NCT05741476 · Allergy, Peanut DBV712, Placebo | DBVT DBV Technologies | Phase 3 | Active, not recruiting | 600 | Nov 6, 2025 | Registry ↗ |
| Jan 15, 2026 | Expanded Access Protocol of Viaskin® Peanut (DBV712) in Peanut-allergic Children NCT05424731 · Peanut Allergy DBV712 250 mcg | DBVT DBV Technologies | — | Available | — | — | Registry ↗ |
| Jun 18, 2025 | Efficacy and Safety of Viaskin Peanut in Children With Immunoglobulin E (IgE)-Mediated Peanut Aller… NCT02636699 · Peanut Allergy Viaskin Peanut 250mcg, Placebo | DBVT DBV Technologies | Phase 3 | Completed | 500 | Aug 18, 2017 | Registry ↗ |
| Dec 16, 2024 | Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age NCT03211247 · Peanut Allergy Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg | DBVT DBV Technologies | Phase 3 | Completed | 414 | Aug 20, 2019 | Registry ↗ |
| Nov 20, 2024 | Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy NCT02223182 · Food Allergy Viaskin Milk 150 mcg, Viaskin Milk 300 mcg | DBVT DBV Technologies | Phase 1/2 | Completed | 198 | Dec 14, 2017 | Registry ↗ |
| Aug 11, 2022 | Diagnostic Accuracy and Safety of DBV1605 for the Diagnosis of Non-IgE Mediated Cow's Milk Allergy… NCT04492683 · Cow's Milk Allergy DBV1605 | DBVT DBV Technologies | Phase 2 | Unknown | 230 | Mar 2024 | Registry ↗ |
| Jun 30, 2022 | Follow-up of the VIPES Study to Evaluate Efficacy and Safety of Viaskin Peanut in Adults and Childr… NCT01955109 · Peanut Allergy Viaskin Peanut 250 mcg | DBVT DBV Technologies | Phase 2 | Completed | 171 | Sep 2016 | Registry ↗ |
| Oct 27, 2021 | Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy NCT01675882 · Peanut Allergy Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg | DBVT DBV Technologies | Phase 2 | Completed | 221 | Jul 2014 | Registry ↗ |
| May 28, 2021 | Viaskin® Peanut (DBV712) Expanded Access Protocol NCT04371627 · Peanut Allergy Viaskin Peanut | DBVT DBV Technologies | — | No longer available | — | — | Registry ↗ |
| Dec 2, 2020 | Follow-up of the PEPITES Study to Evaluate Long-term Efficacy and Safety of Viaskin Peanut in Child… NCT03013517 · Peanut Allergy Viaskin Peanut 250µg | DBVT DBV Technologies | Phase 3 | Active, not recruiting | 300 | Nov 23, 2019 | Registry ↗ |
| Mar 2, 2020 | Viaskin Pertussis Vaccine Trial NCT03035370 · Whooping Cough Viaskin PT 25 mcg, Viaskin PT 50 mcg | DBVT DBV Technologies | Phase 1 | Completed | 102 | Apr 25, 2018 | Registry ↗ |
| Jul 26, 2019 | A Study to Assess the Biological Potency of Peanut Allergen Extract in Adolescent and Adult Peanut… NCT03352726 · Peanut Allergy DBV712 IHRP | DBVT DBV Technologies | Phase 1 | Completed | 27 | Jun 29, 2018 | Registry ↗ |
15 items, most recent first (up to 50). Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 5:54 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances